REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that company management will participate in two upcoming investor conferences in November.
Details of the events are as follows:
Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, MA
Jefferies Global Healthcare Conference, November 16-19, 2026, London, UK
The live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Penelope Belnap
Precision AQ
Penelope.belnap@precisionaq.com
| Nov-05 | |
| Oct-30 | |
| Oct-22 | |
| Sep-30 | |
| Sep-28 | |
| Sep-28 | |
| Sep-28 | |
| Sep-25 | |
| Sep-02 | |
| Sep-01 | |
| Aug-31 | |
| Aug-27 | |
| Aug-05 | |
| Jul-21 | |
| May-14 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite